July 15, 2016 7:23am
… “Our” universe is lately a pure sentiment trade
With fundamentals needing to catch-up, it will be a “rough ride” quarter
… Don’t be fooled by Brainstorm’s (BCLI) and LifeScience Advisors pre-release PR “stunt” and forget lipstick put “high heels and a short dress” on a pig to increase speculation. BCLI might go up initially but, will trip over the hype shortly
I offer a tool set of pertinent facts and targeted analysis defining the who, when, where, which and what of it!
Where is today’s market going – subscribe and find out!
Where do investors turn for insight and perspective - I say intelligently what others won't, so you can do what others can't!
Companies in the headlights: BCLI, BLUE and CLLS
Indexes and ETFs: The IBB (-0.08) and XLV (-0.19%) the IWM (-0.07%) are DOWN while the XBI (+0.04%) is UP
Dow futures are DOWN -0.08% and NASDAQ futures are DOWN -0.08%
U.S. stock indexes were called lower on Friday, as European shares fell following a terror attack in France that killed at least 84 people.
European stocks opened lower as investor sentiment was dampened by an attack in France in which a man drove a truck into a crowd of people celebrating Bastille Day, killing at least 80 people.
Asia markets closed mixed as investors digested a data deluge from China, although stocks still managed to post weekly gains.
The stem, cell, gene and regenerative therapy (SCG&RT) sector closed NEGATIVE on Thursday and Wednesday, POSITIVE on Tuesday, NEGATIVE on Monday and POSITIVE on last Friday.
The SCG&RT sector’s record after the last 5 days (of 43 covered companies):
- Thursday closed NEGATIVE with 22 decliners, 16 advancers and 5 flats
- Wednesday closed Wednesday with 29 decliners, 13 advancers and 1 flat;
- Tuesday closed POSITIVE with 16 decliners, 24 advancers and 3 flats;
- Monday closed NEGATIVE with 25 decliners, 16 advancers and 2 flats;
- Last, Friday closed POSITIVE with 13 decliners, 29 advancers and 1 flat;
Remembering Thursday’s post, “Fundamentals and technicals are weak, how much pain can we afford while the sector juggles the overbought and oversold.”
- Facts in “our” universe are undermined by emotion.
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?
Watch list:
- The iShares Nasdaq Biotechnology (IBB) closed Thursday up +0.25% and is DOWN -0.08% in Friday’s pre-market;
- The SPDR S&P Biotech ETF (XBI) closed Thursday down -0.11% and is UP +0.04% in Friday’s pre-market;
- The Health Care Select Sector SPDR ETF (XLV) closed up Thursday +0.43% and DOWN -0.19% in Friday’s pre-market;
- The iShares Russell 2000 (IWM) closed Thursday up +0.10% and is DOWN -0.07% in Friday’s pre-market.
Companies in my spotlight:
bluebird bio (BLUE) closed DOWN -$0.97 to $45.55 after Wednesday closed at $46.52 (-$3.46). A glaring oversold based on what, another’s issue (JUNO and KITE) – Maintaining BUY;
Brainstorm (BCLI) closed UP +$0.88 to $3.56. BCLI announced it would release top line results from the U.S. P2 Study of NurOwn in patients with Amyotrophic Lateral Sclerosis (ALS) on Monday. What’s with the holding pattern – PURE HYPE to increase speculation, I would fall for it! Once results are identified, the stock price based on historical patterns would decline and an offering would suddenly be “pushed” through for capital access. LifeScience Advisors is typically “putting high heels on their PR efforts”, releases are not a fashion show but, a stunt - I’d be EARLY and – SELL;
Cellectis SA (CLLS) closed DOWN -$0.29 to $25.56 after Wednesday’s $25.85 (+$0.44). CLLS bounced down hard due to another’s issues (JUNO) as low as $25.15 last Friday. The aftermarket is positive and UP +$0.19 or +0.74% - Maintaining BUY
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
